|1.||Beyer, Ulrich: 6 articles (04/2010 - 04/2007)|
|2.||Dougherty, Frank C: 6 articles (04/2010 - 11/2006)|
|3.||Locatelli, Francesco: 5 articles (11/2013 - 07/2007)|
|4.||Cases, Aleix: 4 articles (01/2015 - 05/2007)|
|5.||Villa, Giuseppe: 4 articles (11/2013 - 01/2008)|
|6.||Reigner, Bruno: 4 articles (01/2012 - 11/2006)|
|7.||Endo, Koichi: 3 articles (12/2015 - 01/2012)|
|8.||Tashiro, Yoshihito: 3 articles (12/2015 - 01/2012)|
|9.||Hirata, Michinori: 3 articles (12/2015 - 01/2012)|
|10.||Aizawa, Ken: 3 articles (12/2015 - 01/2012)|
11/01/2013 - "The CARISMA study aim was to evaluate the efficacy, safety and tolerability of a once-monthly continuous erythropoietin receptor activator (CERA) for the treatment of anemia in CKD-5D patients. "
07/01/2012 - "[The efficacy and safety of continuous erythropoietin receptor activator in dialytic patients with chronic renal anemia: an open, randomized, controlled, multi-center trial]."
01/01/2014 - "Cost-effectiveness of continuous erythropoietin receptor activator in anemia."
11/01/2013 - "Efficacy and safety of once-monthly continuous erythropoietin receptor activator in patients with chronic renal anemia."
10/01/2012 - "All patients received CERA (Mircera; Roche, Basel, Switzerland) subcutaneously in dose of 0.6 microg per kg every two weeks during the correction phase of anemia treatment or once monthly during the maintenance treatment. "
|2.||Kidney Diseases (Kidney Disease)
12/01/2006 - "This dose-finding, open-label study examined the potential of subcutaneous Continuous Erythropoietin Receptor Activator (C.E.R.A.) to correct anaemia at extended administration intervals in 61 erythropoiesis-stimulating agent-naïve patients with chronic kidney disease (CKD) on dialysis. "
12/01/2006 - "Continuous Erythropoietin Receptor Activator (C.E.R.A.) administered at extended administration intervals corrects anaemia in patients with chronic kidney disease on dialysis: a randomised, multicentre, multiple-dose, phase II study."
01/01/2015 - "Randomized Controlled Trial of Darbepoetin α Versus Continuous Erythropoietin Receptor Activator Injected Subcutaneously Once Every Four Weeks in Patients with Chronic Kidney Disease at the Pre-Dialysis Stage."
10/01/2014 - "Dose equivalence between continuous erythropoietin receptor activator (CERA), Darbepoetin and Epoetin in patients with advanced chronic kidney disease."
01/01/2014 - "Efficacy & safety of continuous erythropoietin receptor activator (CERA) in treating renal anaemia in diabetic patients with chronic kidney disease not on dialysis."
|3.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
10/01/2010 - "Effects of CERA (continuous erythropoietin receptor activator) in patients with advanced non-small-cell lung cancer (NSCLC) receiving chemotherapy: results of a phase II study."
01/01/2007 - "(Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy."
12/01/2007 - "This study assessed injection site pain following subcutaneous (SC) administration with a continuous erythropoietin receptor activator (C.E.R.A.), compared with darbepoetin alfa in healthy adults. "
12/01/2007 - "Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa."
|5.||Nephrotic Syndrome (Syndrome, Nephrotic)
01/01/2012 - "In this study, we examined whether continuous erythropoietin receptor activator (CERA), a long-acting ESA, could prevent kidney injury, especially podocyte damage, in a rat model of nephrotic syndrome induced by puromycin aminonucleoside (PAN). "
01/01/2012 - "Renoprotection by continuous erythropoietin receptor activator in puromycin aminonucleoside-induced nephrotic syndrome."
|1.||darbepoetin alfa (Aranesp)
|3.||Polyethylene Glycols (Polyethylene Glycol)
|7.||Epoetin Alfa (Epogen)
|8.||Procollagen-Proline Dioxygenase (Prolyl Hydroxylase)
|1.||Drug Therapy (Chemotherapy)
|2.||Transplantation (Transplant Recipients)
|4.||Combination Drug Therapy (Combination Chemotherapy)